Potential of garlic (Allium sativum) in lowering high blood pressure: Mechanisms of action and clinical relevance

Integrated Blood Pressure Control

Volumn 7, Issue , 2014, Pages 71-82

  Ried, Karin ^a   Fakler, Peter ^a  

^a National Institute of Integrative Medicine   (Australia)

Author keywords

Garlic; Hydrogen sulfide (H2S); Hypertension; Nitric oxide (NO); Redox signaling; S allylcysteine

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ARGININE; CYSTATHIONINE BETA SYNTHASE; CYSTATHIONINE GAMMA LYASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GARLIC EXTRACT; HOMOCYSTEINE; HYDROGEN SULFIDE; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; S ALLYLCYSTEINE; SULFIDE; TETRAHYDROBIOPTERIN;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; BODY MASS; DIASTOLIC BLOOD PRESSURE; DISEASE PREDISPOSITION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; GARLIC; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; LIFESTYLE; NUTRITION; OXIDATION REDUCTION POTENTIAL; OXIDATIVE STRESS; PRACTICE GUIDELINE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; SUPPLEMENTATION; SYSTOLIC BLOOD PRESSURE; VASODILATATION; WHITE COAT HYPERTENSION;

EID: 84919647392     PISSN: None     EISSN: 11787104     Source Type: Journal    
DOI: 10.2147/IBPC.S51434     Document Type: Review

References (129)

1. World Heart Federation. Fact Sheet: Cardiovascular Disease Risk Factors. Geneva: World Heart Federation; 2012. Available from: http://www.world-heart-federation.org/press/fact-sheets/cardiovascular-disease-risk-factors/. Accessed November 12, 2014.
2. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371(9623):1513-1518.
3. Martiniuk AL, Lee CM, Lawes CM, et al. Hypertension: its prevalence and population-attributable fraction for mortality from cardiovascular disease in the Asia-Pacific region. J Hypertens. 2007;25(1):73-79.
4. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-1913.
5. Denker MG, Cohen DL. What is an appropriate blood pressure goal for the elderly: review of recent studies and practical recommendations. Clin Interv Aging. 2013;8:1505.
6. Bangalore S, Messerli FH, Wun CC, et al. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J. 2010;31(23):2897-2908.
7. Briganti EM, Shaw JE, Chadban SJ, et al. Untreated hypertension among Australian adults: the 1999-2000 Australian Diabetes, Obesity and Lifestyle Study. Med J Aust. 2003;179(3):135-139.
8. Myers MG. The great myth of office blood pressure measurement. J Hypertens. 2012;30(10):1894-1898.
9. Conen D, Bamberg F. Noninvasive 24-h ambulatory blood pressure and cardiovascular disease: a systematic review and meta-analysis. J Hypertens. 2008;26(7):1290-1299.
10. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. J Hypertens. 2007;25(11):2193-2198.
11. Glen SK, Elliott HL, Curzio JL, Lees KR, Reid JL. White-coat hypertension as a cause of cardiovascular dysfunction. Lancet. 1996;348(9028): 654-657.
12. Centers for Disease Control and Prevention. Vital signs: prevalence, treatment, and control of hypertension - United States, 1999-2002 and 2005-2008. MMWR Morb Mortal Wkly Rep. 2011;60(4):103.
13. Chobanian AV, Bakris GL, Black HR, et al. The 7th report of the joint national committee on prevention detection evaluation and treatment of high blood pressure. JAMA. 2003;289(19):2560-2572.
14. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51(6):1403-1419.
15. National Heart Foundation of Australia (National Blood Pressure and Vascular Disease Advisory Committee). Guide to management of hypertension 2008. Updated Dec 2010.
16. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281-1357.
17. Hobbs F, Irwin P, Rubner J. Evidence-based treatment of hypertension: what’s the role of angiotensin II receptor blockers? Br J Cardiol. 2005;12(1):65-70.
18. Olsen H, Klemetsrud T, Stokke HP, Tretli S, Westheim A. Adverse drug reactions in current antihypertensive therapy: a general practice survey of 2586 patients in Norway. Blood Press. 1999;8(2):94-101.
19. Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens. 2002;16(8):569-575.
20. Simons LA, Ortiz M, Calcino G. Persistence with antihypertensive medication: Australia-wide experience, 2004-2006. Med J Aust. 2008;188(4):224-227.
21. Caro JJ, Speckman JL, Salas M, Raggio G, Jackson J. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. Can Med Assoc J. 1999;160(1):41-46.
22. Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006;47(3):345-351.
23. Oliveria SA, Lapuerta P, McCarthy BD, L’Italien GJ, Berlowitz DR, Asch SM. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med. 2002;162(4):413-420.
24. Burnier M. Long-term compliance with antihypertensive therapy: another facet of chronotherapeutics in hypertension. Blood Press Monit. 2000;5(Suppl 1):S31-S34.
25. Korner PI. Essential Hypertension and its Causes: Neural and Non-Neural Mechanisms. Oxford: Oxford University Press; 2007.
26. Mo R, Omvik P, Lund-Johansen P. The Bergen blood pressure study: offspring of two hypertensive parents have significantly higher blood pressures than offspring of one hypertensive and one normotensive parent. J Hypertens. 1995;13(12 pt 2):1614-1617.
27. Witham MD, Nadir MA, Struthers AD. Effect of vitamin D on blood pressure: a systematic review and meta-analysis. J Hypertens. 2009;27(10):1948.
28. Souberbielle JC, Body JJ, Lappe JM, et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: recommendations for clinical practice. Autoimmun Rev. 2010;9(11):709-715.
29. Groppelli A, Giorgi DM, Omboni S, Parati G, Mancia G. Persistent blood pressure increase induced by heavy smoking. J Hypertens. 1992;10(5):495-499.
30. McCraty R, Atkinson M, Tomasino D. Impact of a workplace stress reduction program on blood pressure and emotional health in hypertensive employees. J Altern Complement Med. 2003;9(3):355-369.
31. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 pt B):2960-2984.
32. Juraschek SP, Guallar E, Appel LJ, Miller ER 3rd. Effects of vitamin C supplementation on blood pressure: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2012;95(5):1079-1088.
33. Mente A, O’Donnell MJ, Rangarajan S, et al. Association of urinary sodium and potassium excretion with blood pressure. N Engl J Med. 2014;371(7):601-611.
34. O’Donnell M, Mente A, Rangarajan S, et al. Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med. 2014;371(7):612-623.
35. Ried K, Fakler P. Protective effect of lycopene on serum cholesterol and blood pressure: meta-analyses of intervention trials. Maturitas. 2011;68(4):299-310.
36. Ried K, Sullivan TR, Fakler P, Frank OR, Stocks NP. Effect of chocolate on blood pressure. Cochrane Database Syst Rev. 2012;8:CD008893.
37. MacLennan AH, Myers SP, Taylor AW. The continuing use of complementary and alternative medicine in South Australia: costs and beliefs in 2004. Med J Aust. 2006;184(1):27-31.
38. Harris P, Rees R. The prevalence of complementary and alternative medicine use among the general population: a systematic review. Complement Ther Med. 2000;8(2):88-96.
39. Yeh GY, Davis RB, Phillips RS. Use of complementary therapies in patients with cardiovascular disease. Am J Cardiol. 2006;98(5): 673-680.
40. Lin MC, Nahin R, Gershwin ME, Longhurst JC, Wu KK. State of complementary and alternative medicine in cardiovascular, lung, and blood research executive summary of a workshop. Circulation. 2001;103(16):2038-2041.
41. Gohar F, Greenfield SM, Beevers DG, Lip GY, Jolly K. Self-care and adherence to medication: a survey in the hypertension outpatient clinic. BMC Complement Altern Med. 2008;8:4.
42. Rivlin RS. Historical perspective on the use of garlic. J Nutr. 2001;131(Suppl 3):951S-954S.
43. Petrovska BB, Cekovska S. Extracts from the history and medical properties of garlic. Pharmacogn Rev. 2010;4(7):106.
44. Moyers SB. Garlic in Health, History, and World Cuisine. St Petersburg: Suncoast Press; 1996.
45. Ried K. Effect of garlic on blood pressure, serum cholesterol and immunity: updated meta-analyses and review. J Nutr. 2014.
46. McInnes GT. Lowering blood pressure for cardiovascular risk reduction. J Hypertens Suppl. 2005;23(1):S3-S8.
47. Ried K, Frank OR, Stocks NP. Aged garlic extract lowers blood pressure in patients with treated but uncontrolled hypertension: a randomised controlled trial. Maturitas. 2010;67:144-150.
48. Ried K, Frank OR, Stocks NP, Fakler P, Sullivan T. Effect of garlic on blood pressure: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2008;8:13.
49. Reinhart KM, Coleman CI, Teevan C, Vachhani P, White CM. Effects of garlic on blood pressure in patients with and without systolic hypertension: a meta-analysis. Ann Pharmacother. 2008;42(12):1766-1771.
50. Ried K, Frank OR, Stocks NP. Aged garlic extract reduces blood pressure in hypertensives: a dose-response trial. Eur J Clin Nutr. 2013;67:64-70.
51. Amagase H. Clarifying the real bioactive constituents of garlic. J Nutr. 2006;136(Suppl 3):716S-725S.
52. Yun HM, Ban JO, Park KR, et al. Potential therapeutic effects of functionally active compounds isolated from garlic. Pharmacol Ther. 2014;142(2):183-195.
53. Amagase H, Petesch BL, Matsuura H, Kasuga S, Itakura Y. Intake of garlic and its bioactive components. J Nutr. 2001;131(3):955S-962S.
54. Lawson LD, Wang ZJ. Low allicin release from garlic supplements: a major problem due to the sensitivities of alliinase activity. J Agric Food Chem. 2001;49(5):2592-2599.
55. Lawson LD, Gardner CD. Composition, stability, and bioavailability of garlic products used in a clinical trial. J Agric Food Chem. 2005;53(16): 6254-6261.
56. Harauma A, Moriguchi T. Aged garlic extract improves blood pressure in spontaneously hypertensive rats more safely than raw garlic. J Nutr. 2006;136(Suppl 3):769S-773S.
57. Kodera Y, Suzuki A, Imada O, et al. Physical, chemical, and biological properties of s-allylcysteine, an amino acid derived from garlic. J Agric Food Chem. 2002;50(3):622-632.
58. Hoshino T, Kashimoto N, Kasuga S. Effects of garlic preparations on the gastrointestinal mucosa. J Nutr. 2001;131(3s):1109S-1113S.
59. Beck E, Gruenwald J. Allium sativum in der Stufentherapie der Hyperlipidaemie. Med Welt. 1993;44:516-520.
60. Borrelli F, Capasso R, Izzo AA. Garlic (Allium sativum L.): adverse effects and drug interactions in humans. Mol Nutr Food Res. 2007; 51(11):1386-1397.
61. Waring RH, Klovrza LZ, Harris RM. Diet and individuality in detoxification. J Nutr Environ Med. 2007;16(2):95-105.
62. Meletis CD. Cleansing of the human body. A daily essential process. Altern Complement Ther. 2001;7(4):196-202.
63. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs. 2009;69(13): 1777-1798.
64. Macan H, Uykimpang R, Alconcel M, et al. Aged garlic extract may be safe for patients on warfarin therapy. J Nutr. 2006;136(Suppl 3):793S-795S.
65. Braun L, Cohen M. Herbs and Natural Supplements: An Evidence-Based Guide. Chatswood: Elsevier; 2007.
66. Al-Qattan KK, Thomson M, Al-Mutawa’a S, Al-Hajeri D, Drobiova H, Ali M. Nitric oxide mediates the blood-pressure lowering effect of garlic in the rat two-kidney, one-clip model of hypertension. J Nutr. 2006;136(Suppl 3):774S-776S.
67. Sharifi AM, Darabi R, Akbarloo N. Investigation of antihypertensive mechanism of garlic in 2K1C hypertensive rat. J Ethnopharmacol. 2003;86(2-3):219-224.
68. Morihara N, Sumioka I, Moriguchi T, Uda N, Kyo E. Aged garlic extract enhances production of nitric oxide. Life Sci. 2002;71(5):509-517.
69. Benavides GA, Squadrito GL, Mills RW, et al. Hydrogen sulfide mediates the vasoactivity of garlic. Proc Natl Acad Sci U S A. 2007; 104(46):17977-17982.
70. Chuah SC, Moore PK, Zhu YZ. S-allylcysteine mediates cardioprotection in an acute myocardial infarction rat model via a hydrogen sulfide-mediated pathway. Am J Physiol Heart Circ Physiol. 2007;293(5):H2693-H2701.
71. Shouk R, Abdou A, Shetty K, Sarkar D, Eid A. Mechanisms underlying the antihypertensive effects of garlic bioactives. Nutr Res. 2014;34:106-115.
72. Kirby BS, Crecelius AR, Voyles WF, Dinenno FA. Vasodilatory responsiveness to adenosine triphosphate in ageing humans. J Physiol. 2010;588(20):4017-4027.
73. Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2012;33(7):829-837.
74. Panza JA, García CE, Kilcoyne CM, Quyyumi AA, Cannon RO. Impaired endothelium-dependent vasodilation in patients with essential hypertension evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation. 1995;91(6): 1732-1738.
75. Montezano AC, Touyz RM. Reactive oxygen species and endothelial function-role of nitric oxide synthase uncoupling and Nox family nicotinamide adenine dinucleotide phosphate oxidases. Basic Clin Pharmacol Toxicol. 2012;110(1):87-94.
76. Jones DP. Redefining oxidative stress. Antioxid Redox Signal. 2006; 8(9-10):1865-1879.
77. Jones DP, Park Y, Gletsu-Miller N, et al. Dietary sulfur amino acid effects on fasting plasma cysteine/cystine redox potential in humans. Nutrition. 2011;27(2):199-205.
78. Sies H. Oxidative stress: oxidants and antioxidants. Exp Physiol. 1997;82(2):291-295.
79. Linnane AW, Kios M, Vitetta L. Healthy aging: regulation of the metabolome by cellular redox modulation and prooxidant signaling systems: the essential roles of superoxide anion and hydrogen peroxide. Biogerontology. 2007;8(5):445-467.
80. Finkel T. Signal transduction by reactive oxygen species. J Cell Biol. 2011;194(1):7-15.
81. Halliwell B. Free radicals and antioxidants - quo vadis? Trends Pharmacol Sci. 2011;32(3):125-130.
82. Lee MY, Griendling KK. Redox signaling, vascular function, and hypertension. Antioxid Redox Signal. 2008;10(6):1045-1059.
83. Touyz RM, Briones AM. Reactive oxygen species and vascular biology: implications in human hypertension. Hypertens Res. 2011;34(1): 5-14.
84. Majzunova M, Dovinova I, Barancik M, Chan J. Redox signaling in pathophysiology of hypertension. J Biomed Sci. 2013;20(1):69.
85. Sugiyama T, Michel T. Thiol-metabolizing proteins and endothelial redox state: differential modulation of eNOS and biopterin pathways. Am J Physiol (Cell Physiol). 2010;22(1):H194.
86. Chen C-A, Wang T-Y, Varadharaj S, et al. S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature. 2010;468(7327):1115-1118.
87. Weiss N, Papatheodorou L, Morihara N, Hilge R, Ide N. Aged garlic extract restores nitric oxide bioavailability in cultured human endothelial cells even under conditions of homocysteine elevation. J Ethnopharmacol. 2013;145(1):162-167.
88. Cohen RA, Adachi T. Nitric oxide induced vasodilatation: regulation by physiologic S-glutathiolation and pathologic oxidation of the sarcoplasmic endoplasmic reticulum calcium ATPase. Trends Cardiovasc Med. 2006;16(4):109-114.
89. Foster MW, Hess DT, Stamler JS. Protein S-nitrosylation in health and disease: a current perspective. Trends Mol Med. 2009;15(9):391-404.
90. Pall ML. The NO/ONOO-cycle as the central cause of heart failure. Int J Mol Sci. 2013;14(11):22274-22330.
91. Sarkar S, Korolchuk VI, Renna M, et al. Complex inhibitory effects of nitric oxide on autophagy. Mol Cell. 2011;43(1):19-32.
92. Blagosklonny MV. Answering the ultimate question "what is the proximal cause of aging?". Aging (Albany NY). 2012;4(12):861.
93. Wang R. Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. Physiol Rev. 2012;92(2):791-896.
94. Zhang Y, Tang Z-H, Ren Z, et al. Hydrogen sulfide, the next potent preventive and therapeutic agent in aging and age-associated diseases. Mol Cell Biol. 2013;33(6):1104-1113.
95. Lake-Bruse KD, Faraci FM, Shesely EG, Maeda N, Sigmund CD, Heistad DD. Gene transfer of endothelial nitric oxide synthase (eNOS) in eNOS-deficient mice. Am J Physiol (Heart Circ Physiol). 1999;277(2):H770-H776.
96. Yan H, Du J, Tang C. The possible role of hydrogen sulfide on the pathogenesis of spontaneous hypertension in rats. Biochem Biophys Res Commun. 2004;313(1):22-27.
97. Zhao X, Zhang L-K, Zhang C-Y, et al. Regulatory effect of hydrogen sulfide on vascular collagen content in spontaneously hypertensive rats. Hypertens Res. 2008;31(8):1619-1630.
98. Jiang B, Tang G, Cao K, Wu L, Wang R. Molecular mechanism for H2S-induced activation of KATP channels. Antioxid Redox Signal. 2010;12(10):1167-1178.
99. Kolluru GK, Shen X, Kevil CG. A tale of two gases: NO and H2S, foes or friends for life? Redox Biol. 2013;1(1):313-318.
100. Predmore BL, Lefer DJ, Gojon G. Hydrogen sulfide in biochemistry and medicine. Antioxid Redox Signal. 2012;17(1):119-140.
101. Kashfi K, Olson KR. Biology and therapeutic potential of hydrogen sulfide and hydrogen sulfide-releasing chimeras. Biochem Pharmacol. 2013;85(5):689-703.
102. Chuah SC, Moore PK, Zhu YZ. S-allylcysteine mediates cardioprotection in an acute myocardial infarction rat model via a hydrogen sulfide-mediated pathway. Am J Physiol Heart Circ Physiol. 2007;293(5):H2693-H2701.
103. Predmore BL, Alendy MJ, Ahmed KI, Leeuwenburgh C, Julian D. The hydrogen sulfide signaling system: changes during aging and the benefits of caloric restriction. Age. 2010;32(4):467-481.
104. Ames BN. Low micronutrient intake may accelerate the degenerative diseases of aging through allocation of scarce micronutrients by triage. Proc Natl Acad Sci U S A. 2006;103(47):17589-17594.
105. Yoshinori M, Norihiro S, Yuka K, Noriyuki N, Yuki O, Hideo K. Thioredoxin and dihydrolipoic acid are required for 3-mercaptopyruvate sulfurtransferase to produce hydrogen sulfide. Biochem J. 2011;439(3): 479-485.
106. Nikolaidis MG, Jamurtas AZ. Blood as a reactive species generator and redox status regulator during exercise. Arch Biochem Biophys. 2009;490(2):77-84.
107. Olson KR. A practical look at the chemistry and biology of hydrogen sulfide. Antioxid Redox Signal. 2012;17(1):32-44.
108. Wang R. Is H2S a stinky remedy for atherosclerosis? Arterioscler Thromb Vasc Biol. 2009;29(2):156-157.
109. Schalinske KL, Smazal AL. Homocysteine imbalance: a pathological metabolic marker. Adv Nutr. 2012;3(6):755-762.
110. Moat SJ, McDowell IF. Homocysteine and endothelial function in human studies. Semin Vasc Med. 2005;5(2):172-182.
111. Weiss N, Keller C, Hoffmann U, Loscalzo J. Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia. Vasc Med. 2002;7(3):227-239.
112. Tayama J, Munakata M, Yoshinaga K, Toyota T. Higher plasma homocysteine concentration is associated with more advanced systemic arterial stiffness and greater blood pressure response to stress in hypertensive patients. Hypertens Res. 2006;29(6):403.
113. Mizrahi EH, Noy S, Sela B-A, Fleissig Y, Arad M, Adunsky A. Further evidence of interrelation between homocysteine and hypertension in stroke patients: a cross-sectional study. Isr Med Assoc J. 2003;5(11):791-794.
114. Mangoni AA, Zinellu A, Carru C, Attia JR, McEvoy M. Serum thiols and cardiovascular risk scores: a combined assessment of transsulfuration pathway components and substrate/product ratios. J Transl Med. 2013;11(1):1-9.
115. Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual? Arch Intern Med. 2000;160(4):422-434.
116. Clarke R, Bennett DA, Parish S, et al. Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias. PLoS Med. 2012;9(2):e1001177.
117. Smith AD. The worldwide challenge of the dementias: a role for B vitamins and homocysteine? Food Nutr Bull. 2008;29(Suppl 1): 143-172.
118. Smith AD, Smith SM, De Jager CA, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One. 2010;5(9):e12244.
119. Beard RS, Bearden SE. Vascular complications of cystathionine β-synthase deficiency: future directions for homocysteine-to-hydrogen sulfide research. Am J Physiol Heart Circ Physiol. 2011;300(1): H13-H26.
120. Finkelstein JD, Martin JJ. Homocysteine. Int J Biochem Cell Biol. 2000;32(4):385-389.
121. Kraus JP, Janošik M, Kožich V, et al. Cystathionine β-synthase mutations in homocystinuria. Hum Mutat. 1999;13(5):362-375.
122. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet. 1985;37(1):1.
123. Skovby F, Gaustadnes M, Mudd SH. A revisit to the natural history of homocystinuria due to cystathionine β-synthase deficiency. Mol Genet Metab. 2010;99(1):1-3.
124. d’Emmanuele di Villa Bianca R, Mitidieri E, Di Minno MN, et al. Hydrogen sulphide pathway contributes to the enhanced human platelet aggregation in hyperhomocysteinemia. Proc Natl Acad Sci U S A. 2013;110(39):15812-15817.
125. Ingenbleek Y, McCully KS. Vegetarianism produces subclinical malnutrition, hyperhomocysteinemia and atherogenesis. Nutrition. 2012;28(2):148-153.
126. Muda P, Kampus P, Zilmer M, et al. Homocysteine and red blood cell glutathione as indices for middle-aged untreated essential hypertension patients. J Hypertens. 2003;21(12):2329-2333.
127. Budoff MJ, Takasu J, Flores FR, et al. Inhibiting progression of coronary calcification using Aged Garlic Extract in patients receiving statin therapy: a preliminary study. Prev Med. 2004;39(5): 985-991.
128. Yeh YY, Yeh SM. Homocysteine-lowering action is another potential cardiovascular protective factor of aged garlic extract. J Nutr. 2006;136(Suppl 3):745S-749S.
129. Al-Qattan KK, Khan I, Alnaqeeb MA, Ali M. Mechanism of garlic (Allium sativum) induced reduction of hypertension in 2K-1C rats: a possible mediation of Na/H exchanger isoform-1. Prostaglandins Leukot Essent Fatty Acids. 2003;69(4):217-222.